Treatments for relapsing, refractory multiple myeloma: A health technology assessment
Evaluation of the clinical and cost-effectiveness of the increasing number of treatments available for patients who experience relapsed or refractory multiple myeloma (RRMM).
About the project
-
Project period: 30.03.2020 - 30.06.2021 (Active)
- Coordinating Institution: Norwegian Institute of Public Health
-
Project Manager:
- Arna Sue Desser, Norwegian Institute of Public Health
-
Project Participants:
- Fredrik Schjesvold, Oslo University Hospital
- Mats Irgen Olsen, University Hospital of North Norway
- Olav Ljøsne, The norwegian Leukemia Association
- Einar Haukås, Stavanger Hospital Trust - Stavanger University Hospital
- Ulrikke Højslev Lund, Norwegian Institute of Public Health
- Christopher James Rose, Norwegian Institute of Public Health
- Gunn Eva Næss, Norwegian Institute of Public Health
- Elisabet Vivianne Hafstad, Norwegian Institute of Public Health
- Anna Lien Espeland, Norwegian Institute of Public Health
- Liv Giske, Norwegian Institute of Public Health
- Ingrid Kristine Ohm, Norwegian Institute of Public Health
- Project plan: Prosjektplan for behandling av myelomatose_ID2019_072_.pdf
Summary
Multiple myeloma (MM), the second most common type of blood cancer, reduces the body’s ability to fight infection and can lead to anemia, bone damage, nerve damage, kidney damage, etc. Approximately 450 Norwegians are diagnosed with myeloma annually. Because there is currently no cure for myeloma, it is important to evaluate the clinical and cost-effectiveness of the increasing number of treatments available for patients who experience relapsed or refractory multiple myeloma (RRMM).